Postoperative Outcomes in Vedolizumab-Treated Patients Undergoing Abdominal Operations for Inflammatory Bowel Disease
Journal of Crohn's & colitis | 21 Aug 2016
AL Lightner, LE Raffals, KL Mathis, RR Cima, CS Tse, JH Pemberton, EJ Dozois and EV Loftus
Vedolizumab was recently FDA approved for treatment of moderate to severe ulcerative colitis (UC) and Crohn’s disease (CD). No study to date has examined the rate of postoperative infectious complications among patients who received vedolizumab in the perioperative period. We sought to determine the 30-day postoperative infectious complication rate among IBD patients who received vedolizumab within 12 weeks of an abdominal operation as compared to patients who received TNFα inhibitors or no biologic therapy.
* Data courtesy of Altmetric.com